Press Release: CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) Published in Science Translational Medicine

Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection

As featured in Science: News Brief January 2021: New strategy to fight world’s most potent poison passes first tests in animals

Tamed botulinum toxin ferries miniature antibodies into nerves to reverse paralysis